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A B S T R A C T
Various C-glucopyranosyl-1,2,4-triazolones were designed as potential inhibitors of glycogen phosphory-
lase. Syntheses of these compounds were performed with O-perbenzoylated glucose derivatives as
precursors. High temperature ring closure of N1-carbamoyl-C-β-D-glucopyranosyl formamidrazone gave
3-β-D-glucopyranosyl-1,2,4-triazol-5-one. Reaction of N1-tosyl-C-β-D-glucopyranosyl formamidrazone
with ClCOOEt furnished 3-β-D-glucopyranosyl-1-tosyl-1,2,4-triazol-5-one. In situ prepared β-D-
glucopyranosylcarbonyl isocyanate was transformed by PhNHNHBoc into 3-β-D-glucopyranosyl-1-phenyl-
1,2,4-triazol-5-one, while the analogous 1-(2-naphthyl) derivative was obtained from the unsubstituted
triazolone by naphthalene-2-boronic acid in a Cu(II) catalyzed N-arylation. Test compounds were pre-
pared by Zemplén deacylation. The new glucose derivatives had weak or no inhibition of rabbit muscle
glycogen phosphorylase b: the best inhibitor was 3-β-D-glucopyranosyl-1-(2-naphthyl)-1,2,4-triazol-5-
one (Ki = 80 μM).
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Glycogen phosphorylase (GP) inhibitors (GPIs) may ﬁnd appli-
cations in antidiabetic therapy especially in type 2 diabetes mellitus,1
but also in other diseases like cerebral2,3 and cardiac4 ischemias, other
cardiovascular impairments,4,5 and tumours.6,7 A very broad range
of compounds with a number of scaffolds was shown to have in-
hibitory effect against GP8 through binding to one (or sometimes
more) of the binding sites discovered so far.9 The catalytic site of
GP can be targeted by glucose derivatives which are competitive in-
hibitors of the enzyme.10,11 Several glucose based GPIs show
submicromolar eﬃciency: the best known inhibitors can be found
among glucopyranosylidene-spiro-heterocycles, N-acyl-N’-β-D-
glucopyranosyl ureas, and C-β-D-glucopyranosyl heterocycles. In the
latter class of compounds structure–activity relationships have been
established for 5-membered heterorings and some of their benzologs
(Chart 1). Thus, 2-β-D-glucopyranosyl benzothiazole 1 proved to be
a weaker inhibitor in comparison to benzimidazole 2.12 This obser-
vation could be rationalized by X-ray crystallography of the enzyme-
inhibitor complexes showing an H-bond between the imidazole NH
and the main chain carbonyl of His377 in the vicinity of the active
site of GP.13 Extension of 2 by a further aromatic ring as in 3 re-
sulted in an even stronger inhibitor indicating that a large
hydrophobic moiety properly protruding into the β-channela of the
enzyme can be beneﬁcial for the binding.14 Studies with each pos-
sible C-glucosyl oxadiazole isomer revealed that the constitution
of the heterocycles was also an important factor and 5-β-D-
glucopyranosyl-3-substituted-1,2,4-oxadiazoles 4 and 7 proved to
be the best inhibitors of these series.15,16 Changing the oxadiazole
to 1,2,4-triazole furnished inhibitors 5 and 8 exhibiting stronger
binding most probably due to the H-bonding capacity of the
triazoles,17,18 and imidazoles 6 and 9 were shown to be even better
inhibitors.19 Although no structural data have yet been available to
rationalize this ﬁnding, one may speculate that the stronger inhi-
bition of imidazoles can be a result of the smaller number of ring
tautomers in comparison to the case of triazoles. Tautomeric forms
have recently been shown to have a very important contribution
to the determination of the binding strength of GP inhibitors.20 The
observation that the naphthyl substituted compounds 7-9 bind stron-
ger to the enzyme than the phenyl substituted 4-6 corroborates the
role of the large hydrophobic group. Based on the above consider-
ations, we have designed 3-C-glucopyranosyl-1-substituted-1,2,4-
triazol-5-ones as further candidates of potential GPIs in which the
presence of the carbonyl group might result in decreasing the
number of tautomers due to the stability of the NHCO moiety.
* Corresponding author. Department of Organic Chemistry, University of Debrecen,
POB 20, H-4010 Debrecen, Hungary. Tel.: +36 52512900 ext 22348; fax: +36
52512744.
E-mail address: somsak@tigris.unideb.hu (L. Somsák).
a The β-channel is an empty space next to the catalytic site of GP in the direc-
tion of the β-anomeric substituent of bound D-glucose surrounded by both polar
and apolar amino acid side chains.
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2. Results and discussion
Several methods were reported for the syntheses of
various 1,2,4-triazol-5-ones,21 e.g. starting with nitriles,22,23
imidates,24 N1-acyl-semicarbazides,25 N1-tosyl-amidrazones,26 or
aldehyde-semicarbazones.27 C-Glycosyl-1,2,4-triazol-5-ones
could not be located in the literature. The only related work
found was that of Poonian and Nowoswiat28 reporting the trans-
formation of β-D-ribofuranosyl formimidate by (thio)semicarbazide
to the corresponding C-β-D-ribofuranosyl-N1-(thio)carbamoyl
formamidrazones. While the ring closure of the thiocarbamoyl de-
rivative to a 1,2,4-triazol-5-thione could be achieved at elevated
temperature, similar attempts to get the corresponding 1,2,4-triazol-
5-one failed.28
Since from earlier work we had in hand the O-perbenzoylated
β-D-glucopyranosyl formimidate14 (10, Table 1), this compound was
used as the starting material for the preparation of some new
amidrazones suitable for ring closure towards the expected 1,2,4-
triazol-5-ones. Reactions of 10 with ethyl carbazate (11),
semicarbazide (12) or 2,4-dinitrophenylhydrazine (13) smoothly gave
the corresponding C-glucosyl formamidrazones 14-16, respectively.
Boiling a solution of 14 in m-xylene brought about the ex-
pected ring closure; however, the reaction was accompanied by a
1,2-elimination of benzoic acid resulting in glucal 18 in low yield
(Scheme 1). Cyclization of N1-carbamoyl-amidrazone 15 in boiling
DMF took place without concomitant elimination producing the ex-
pected triazolone 19 in good yield. Subsequent O-debenzoylation
under Zemplén conditions gave test compound 20. Attempted cy-
clization of 16 with ClCOOEt in CHCl3 in the presence of 2 equiv.
of pyridine or DIPEA at r. t. or with boiling failed; actually, no re-
action could be observed. Reaction26 of tosyl-amidrazone 1717,29with
ClCOOEt produced the tosylated triazolone 21whichwas deprotected
according to the Zemplén protocol to give the test compound 22.
Chart 1. Inhibitory potency (Ki [μM]) of selected C-β-D-glucopyranosyl hetero-
cycles against rabbit muscle glycogen phosphorylase b (RMGPb).
Table 1
Synthesis of O-perbenzoylated N1-substituted C-β-D-glucopyranosyl formamidrazones
a) dry EtOH, reﬂux; b) dry pyridine, rt.
Reagent R Product Conditions Yield (%)
11 14 a 55
12 15 b 80
13 16 a 83
Scheme 1. Reagents and conditions: a) drym-xylene, reﬂux; b) dry DMF, reﬂux; c)
ClCOOEt, dry CHCl3, dry pyridine, 0 °C to rt; d) cat. NaOMe in dry MeOH, rt.
ARTICLE IN PRESS
Please cite this article in press as: Éva Bokor, Zsolt Széles, Tibor Docsa, Pál Gergely, László Somsák, C-Glucopyranosyl-1,2,4-triazol-5-ones: synthesis and inhibition of glycogen
phosphorylase, Carbohydrate Research (2015), doi: 10.1016/j.carres.2015.12.005
2 É. Bokor et al./Carbohydrate Research ■■ (2015) ■■–■■
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
Next we wished to prepare isomers of N-phenyl substituted
triazolones. To obtain 5-β-D-glucopyranosyl-1-phenyl-1,2,4-triazol-
3-one, compound 25 was prepared as the starting material (Scheme
2). C-Glucosyl formamide 2330,31 was converted by oxalyl chloride32
into the acyl isocyanate 24 which was used without puriﬁcation for
the next reaction with PhNHNH2 to give 25 in very good yield.
Towards 3-β-D-glucopyranosyl-1-phenyl-1,2,4-triazol-5-one, inter-
mediate 24 was reacted with Boc-protected PhNHNH2 to give 26.
Treatment of 26 by CF3COOH, in analogywith a reported procedure,33
cleaved the protecting group and spontaneous ring closure gave the
expected triazolone 27. To our surprise, this compound proved iden-
tical with that obtained by heating 25 in m-xylene; however, this
unexpected outcome had a precedent in the literature.34 Besides the
chemical evidence of the route 26→27, spectroscopic veriﬁcation
for the structure of 27 was also sought for. To this end, a 2D 1H-1H
ROESY spectrum was recorded which showed the vicinity of the
triazolone NH to H1 and H2 of the sugar moiety, thereby indicat-
ing the position of the aromatic residue (Fig. 1; for the spectra see
Supporting information). Deprotection of 27 under Zemplén con-
ditions furnished test compound 28 in excellent yield.
In order to have a triazolone with a larger aromatic substitu-
ent, synthesis of the 2-naphthyl derivative was envisaged. Although
a synthetic sequence analogous to 23→24→26→27 seemed straight-
forward, the unavailability of the necessary 2-naphthyl-hydrazine
prevented the application of this route. Therefore, a copper cata-
lyzed cross-coupling protocol for the N-arylation of amides was
adapted.35 The reaction of triazolone 19 with naphthalene-2-
boronic acid in the presence of Cu(OAc)2 and Et3N gave low yield
of 29 (Scheme 3). The structure of this product was considered to
be analogous to that of 27 based on the coincidences of the chem-
ical shifts both in the 1H and 13C NMR spectra of 27 and 29. In
addition, the structure was also corroborated by a 2D 1H-1H ROESY
experiment (Fig. 1; for the spectra, see Supporting information).
Zemplén deprotection of 29 produced test compound 30 in good
yield.
The new compounds were assayed against rabbit muscle gly-
cogen phosphorylase b (RMGPb) as described previously36 (Table 2).
The unsubstituted triazolone 20 and its 1-tosylated derivative 22
had no signiﬁcant effect. In the case of 20, the ineﬃciency may be
explained by the relatively small size of the aglycon which cannot
interact in the β-channel of the enzyme. This resembles the case
of the similarly non inhibitory 5-β-D-glucopyranosyl tetrazole.12 For
22, where the tosyl substituent can occupy the β-channel, the lack
of eﬃciency may be attributed to the presence of the SO2 moiety.
Such a tetrahedral linking element in the aglycon was shown to be
detrimental to the binding in some types of glucose derived
compounds.8,11,38–40 The 1-aryl-substituted triazolones 28 and 30 had
weak inhibitory effects whereby the 2-naphthyl derivative 30 showed
stronger binding than the phenyl compound 28. This reﬂects the
general trend regarding the size and orientation of aryl substitu-
ents that were observed in many cases (cf examples 4-6 vs 7-9 in
Chart 1). On the other hand, the triazolone ring between the sugar
Scheme 2. Reagents and conditions: a) (COCl)2, dry 1,2-dichloroethane, reﬂux; b) dry THF, 0 °C to rt; c) dry m-xylene, reﬂux; d) CF3COOH, dry CH2Cl2, rt; e) cat. NaOMe in
dry MeOH, rt.
Fig. 1. Nuclear Overhauser effects in 1-aryl-3-β-D-glucopyranosyl-1,2,4-triazol-5-
ones 27 (Ar = Ph) and 29 (Ar = 2-naphthyl).
Scheme 3. Reagents and conditions: a) Cu(OAc)2, Et3N, CH2Cl2, rt; b) cat. NaOMe
in dry MeOH, rt.
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and the aromatic part must have insuﬃcient interactions with the
amino acid side chains of RMGPb, resulting in weaker inhibition than
many of other 5-membered C-glucosyl heterocycles studied so far.
In conclusion, synthetic methods have been elaborated to obtain
hitherto unknown 3-β-D-glucopyranosyl-1-(un)substituted-1,2,4-
triazol-5-ones. Enzyme kinetic tests with rabbit muscle glycogen
phosphorylase b revealed 1-aryl-triazolones to be weak inhibi-
tors, thereby contributing to structure–activity relationships of
C-glucosyl heterocycles.
3. Experimental
3.1. General methods
Melting points were measured on a Koﬂer hot-stage and are un-
corrected. Optical rotationswere determinedwith a Perkin-Elmer 241
polarimeter at rt. NMR spectra were recorded with Bruker 360 (360/
90 MHz for 1H/13C) or Bruker 400 (400/100 MHz for 1H/13C)
spectrometers. 2D 1H-1HROESY (400MHz) spectrawere acquiredwith
150ms spinlock formixing in overnight experiments. Chemical shifts
are referenced to Me4Si (1H), or to the residual solvent signals (13C).
Mass spectra were obtained by Thermo Scientiﬁc LTQ XL or
MicroTOF-Q type Qq-TOF MS (Bruker Daltonik, Bremen, Germany)
instruments. TLC was performed on DC-Alurolle Kieselgel 60 F254
(Merck) plates, visualized under UV light and by gentle heating. For
column chromatography, Kieselgel 60 (Merck, particle size 0.063–
0.200mm)was used. Toluene,m-xylene, CH2Cl2, CHCl3were distilled
from P4O10 and stored over 4 Å molecular sieves or sodium wires.
MeOHwas puriﬁed by distillation after reﬂuxing for a couple of hours
withmagnesium turnings and iodine. THFwas distilled from sodium
benzophenone ketyl and stored over sodium wires. Anhydrous
solvents: EtOH (Sigma-Aldrich), DMF (Sigma-Aldrich), 1,2-
dichloroethane (Sigma-Aldrich) and pyridine (VWR) were purchased
from the indicated companies. Ethyl C-(2,3,4,6-tetra-O-benzoyl-
β-D-glucopyranosyl)formimidate14 (10), N1-tosyl-C-(2,3,4,6-
tetra-O-benzoyl-β-D-glucopyranosyl)formamidrazone17 (17),
C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide30 (23) and
PhNHNHBoc41 were synthesized according to published procedures.
3.2. General procedure for removal of benzoyl protecting groups by
the Zemplén protocol
To a solution of an O-perbenzoylated compound in anhydrous
MeOH (5 mL/100 mg, a few drops of anhydrous CHCl3 were added
in case of incomplete dissolution), a catalytic amount of a NaOMe
solution (1 M in MeOH) was added and the mixture was left at rt.
After completion of the reaction monitored by TLC (1:1 EtOAc-
hexane and 7:3 CHCl3-MeOH), the mixture was neutralized with a
cation exchange resin Amberlyst 15 (H+ form), then the resin was
ﬁltered off and the solvent was removed. The crude product was
puriﬁed by column chromatography.
3.3. N1-Ethoxycarbonyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)formamidrazone (14)
Ethyl
C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formimidate14 (10,
1.00 g, 1.53 mmol) and ethyl carbazate (11, 0.16 g 1.53 mmol) were
stirred in anhydrous EtOH (20 mL) at reﬂux temperature, and the
reaction was monitored by TLC (1:1 EtOAc-hexane). After comple-
tion of the reaction (5 h), the mixture was evaporated under
diminished pressure, and the crude product was puriﬁed by column
chromatography (1:1 EtOAc-hexane) to yield 0.60 g (55%) white solid.
Mp: 104–106 °C; [α]D = −21 (c 0.55, CHCl3); 1HNMR (CDCl3) δ (ppm):
8.61 (1H, br s, NH), 8.04–7.82 (8H, m, Ar), 7.57–7.25 (12H, m, Ar),
5.99, 5.74, 5.63 (3 × 1H, 3 pseudo t, J = 9.6, 9.6 Hz in each, H-2, H-3,
H-4), 5.15 (2H, br s, NH2), 4.63 (1H, dd, J = 12.3, < 1 Hz, H-6a), 4.52
(1H, dd, J = 12.3, 5.3 Hz, H-6b), 4.46 (1H, d, J = 9.6 Hz, H-1), 4.25 (1H,
ddd, J = 9.6, 5.3, < 1 Hz, H-5) 3.94 (2H, q, J = 7.0 Hz, CH2), 1.00 (3H,
t, J = 7.0 Hz, CH3); 13C NMR (CDCl3) δ (ppm): 166.0, 165.5 (2), 165.1
(C = O), 155.5 (COOEt), 146.9 (C = N), 133.3–128.1 (Ar), 77.4, 76.0,
73.6, 70.4, 69.2 (C-1 – C-5), 63.0, 61.4 (C-6, CH2), 14.1 (CH3). MS-
ESI (m/z): Calcd. for C38H35N3NaO11+ [M + Na]+: 732.216. Found:
732.216.
3.4. N1-Carbamoyl-C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)formamidrazone (15)
Ethyl
C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formimidate14 (10,
0.10 g, 0.15 mmol) and semicarbazide hydrochloride (12, 0.03 g,
0.31 mmol) were stirred in anhydrous pyridine (3 mL) at rt. After
disappearance of the imidate (3 h) monitored by TLC (EtOAc), the
pyridine was removed under diminished pressure and the residue
was puriﬁed by column chromatography (EtOAc) to give 0.08 g (80%)
white solid. Mp: 131–133 °C; [α]D = +36 (c 0.50, CHCl3); 1H NMR
(CDCl3) δ (ppm): 9.57 (1H, s, NH), 8.02–7.82 (4 × 2H, 4 d, J = 7.3 Hz,
Ar), 7.55–7.24 (12H, m, Ar), 5.94, 5.83, 5.68 (3 × 1H, 3 pseudo t, J = 9.2,
9.2 Hz in each, H-2, H-3, H-4), 5.25 (2H, s, NH2), 4.63 (1H, dd, J = 12.6,
2.6 Hz, H-6a), 4.46 (1H, dd, J = 12.6, 5.3 Hz, H-6b), 4.29 (1H, d,
J = 9.2 Hz, H-1), 4.19 (1H, ddd, J = 9.2, 5.3, 2.6 Hz, H-5); 13C NMR
(CDCl3) δ (ppm): 166.1, 165.8, 165.5, 165.1 (C = O), 159.0 (C = ONH2),
141.5 (C = N), 133.4–133.1, 129.7–128.2 (Ar), 77.2, 76.1, 74.0, 69.7,
69.2 (C-1 – C-5), 63.0 (C-6). MS-ESI (m/z): Calcd. for C36H33N4O10+
[M + H]+: 681.2. Found: 681.7.
3.5. N1-(2,4-Dinitrophenyl)-C-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)formamidrazone (16)
Ethyl
C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formimidate14 (10,
0.10 g, 0.15 mmol) and 2,4-dinitrophenylhydrazine (13, 61 mg,
0.31 mmol) were reﬂuxed in anhydrous EtOH (3 mL), and the re-
action was monitored by TLC (2:3 EtOAc-hexane). After total
consumption of the imidate (1 d), the solvent was removed and the
Table 2
Inhibition of RMGPb by C-glucopyranosyl-1,2,4-triazol-5-ones
Compound Inhibition [μM]
No inhibition at 625 μM
20
No inhibition at 625 μM
22
IC50 350
Ki 191a
28
Ki 80
30
a Calculated from the IC50 by a web-based tool.37
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residue was puriﬁed by column chromatography (3:7 EtOAc-
hexane) to give 0.10 g (83%) red syrup. Rf: 0.50 (2:3 EtOAc-hexane);
[α]D = −66 (c 0.30, CHCl3); 1HNMR (CDCl3) δ (ppm): 10.16 (1H, s, NH),
8.89 (1H, d, J = 2.6 Hz, Ar), 8.04–7.84 (4 × 2H, 4 dd, J = 7.3, 1.0 Hz in
each, Ar), 7.62 (1H, dd, J = 9.6, 2.6 Hz, Ar), 7.54–7.24 (12H, m, Ar),
7.05 (1H, d, J = 9.6 Hz, Ar), 6.11, 5.82, 5.77 (3 × 1H, 3 pseudo t, J = 9.6,
9.6 Hz in each, H-2, H-3, H-4), 5.31 (2H, br s, NH2), 4.75 (1H, dd,
J = 12.6, 2.6 Hz, H-6a), 4.58 (1H, dd, J = 12.6, 5.3 Hz, H-6b), 4.54 (1H,
d, J = 9.6 Hz, H-1), 4.36 (1H, ddd, J = 9.6, 5.3, 2.6 Hz, H-5); 13C NMR
(CDCl3) δ (ppm): 166.3, 165.8, 165.3 (2) (C = O), 150.1, 145.3 (C = N,
DNP-C-1), 137.0 (DNP-C-4), 133.7–133.4, 129.9–128.4 (Ar), 123.2,
116.0 (DNP-C-3, DNP-C-6) 77.0, 76.6, 73.4, 70.5, 69.1 (C-1 – C-5),
63.0 (C-6). MS-ESI (m/z): Calcd. for C41H34N5O13+ [M + H]+: 804.2.
Found: 804.5.
3.6. 3-(3′,4′,6′-Tri-O-benzoyl-2′-deoxy-D-arabino-hex-1′-
enopyranosyl)-1H-1,2,4-triazol-5(4H)-one (18)
The solution of amidrazone 14 (0.40 g, 0.56 mmol) in anhy-
drousm-xylene (8 mL) was heated at 140 °C, and the reaction was
monitored by TLC (4:1 EtOAc-hexane). After total consumption of
the starting material (2 h) the solvent was removed, and the residue
was puriﬁed by column chromatography (7:2 EtOAc-hexane) to yield
0.11 g (37%) pale yellow solid. Mp: 205–207 °C; [α]D = +13 (c 0.51,
DMSO); 1H NMR (DMSO-d6) δ (ppm): 11.92, 11.83 (2 × 1H, 2 s, NH),
7.97–7.93 (6H, m, Ar), 7.67–7.64 (3H, m, Ar), 7.54–7.48 (6H, m, Ar),
5.91 (1H, dd, J = 5.5, 3.7 Hz, H-3′), 5.83 (1H, d, J = 3.7 Hz, H-2′), 5.80
(1H, dd, J = 6.8, 5.5 Hz, H-4′), 5.06 (1H, ddd, J = 6.8, 5.5, 3.1 Hz, H-5′),
4.77 (1H, dd, J = 12.3, 5.5 Hz, H-6′a), 4.66 (1H, dd, J = 12.3, 3.1 Hz,
H-6′b); 13C NMR (DMSO-d6) δ (ppm): 165.3, 165.0, 164.5 (C = O),
155.5 (triazolone C = O), 143.1, 140.4 (C-1′, triazolone C-3), 133.8,
133.7, 133.5, 129.4–128.7 (Ar), 98.1 (C-2′), 74.1, 67.8, 67.0 (C-3′ – C-5′),
61.4 (C-6′). MS-ESI (m/z): Calcd. for C29H24N3O8+ [M + H]+: 542.2.
Found: 542.3.
3.7. 3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1H-1,2,4-
triazol-5(4H)-one (19)
The amidrazone 15 (2.0 g, 2.94 mmol) was reﬂuxed in anhy-
drous DMF (50mL), and the reaction was monitored by TLC (EtOAc).
After disappearance of the starting material (2 h), the solvent was
removed under reduced pressure, and the residue was puriﬁed by
column chromatography (EtOAc) to yield 1.35 g (69%) white solid.
Mp: 281–283 °C; [α]D = −13 (c 0.47, DMSO); 1H NMR (DMSO-d6) δ
(ppm): 11.91, 11.46 (2 × 1H, 2 s, NH), 8.04–7.36 (20H, m, Ar), 6.15,
5.82, 5.69 (3 × 1H, 3 pseudo t, J = 9.2, 9.2 Hz in each, H-2′, H-3′, H-4′),
5.10 (1H, d, J = 9.2 Hz, H-1′), 4.67 (1H, ddd, J = 9.2, 5.3, < 1 Hz, H-5′),
4.53 (2H, s, H-6′a, H-6′b); 13C NMR (DMSO-d6) δ (ppm): 165.3, 165.1,
164.7, 164.3 (C = O), 155.8 (triazolone C = O), 143.3 (triazolone C-3),
133.8–133.4, 129.4–128.3 (Ar), 74.5, 73.8, 71.6, 70.1, 68.6 (C-1′ – C-5′),
62.3 (C-6′). MS-ESI (m/z): Calcd. for C36H30N3O10+ [M + H]+: 664.2.
Found: 664.3.
3.8. 3-(β-D-Glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (20)
Prepared from compound 19 (0.27 g, 0.41 mmol) according to
the general procedure (Section 3.2.). Reaction time: 1 d. Puriﬁed by
column chromatography (5:4 CHCl3-MeOH) to yield 60 mg (60%)
colourless syrup. Rf = 0.32 (1:1 CHCl3-MeOH), [α]D = +9 (c 0.10,
MeOH); 1H NMR (DMSO-d6 + 1 drop D2O) δ (ppm): 4.70 (1H, d,
J = 9.9 Hz, H-1′), 4.46 (1H, dd, J = 11.9, 2.6 Hz, H-6′a), 4.25–4.18 (2H,
m, H-2′ or H-3′ or H-4′, H-6′b), 4.06–4.00 (2H, m, H-2′ or H-3′ or
H-4′, H-5′), 3.93 (1H, pseudo t, J = 9.9, 9.2 Hz, H-2′ or H-3′ or H-4′);
13C NMR (DMSO-d6) δ (ppm): 156.1 (triazolone C = O), 145.7
(triazolone C-3), 81.3, 77.7, 74.7, 71.0, 69.8 (C-1′ – C-5′), 61.1 (C-6′).
MS-ESI (m/z): Calcd. for C8H14N3O6+ [M + H]+: 248.1; C8H13N3NaO6+
[M +Na]+: 270.1. Found: [M +H]+: 248.2; [M +Na]+: 270.5. Anal: Calcd
for C8H13N3O6 (M 247.205): C, 38.87; H, 5.30; N, 17.00. Found: C,
39.09; H, 5.43; N,16.89.
3.9. 3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-tosyl-1H-
1,2,4-triazol-5(4H)-one (21)
To a solution of amidrazone17 17 (0.20 g, 0.25 mmol) in anhy-
drous CHCl3 (3mL) anhydrous pyridine (37 μL, 0.45mmol, 1.8 equiv.)
was added. The mixture was then cooled in an ice bath, and a so-
lution of ethyl chloroformate (36 μl, 0.38mmol, 1.5 ekv.) in anhydrous
CHCl3 (3mL) was added dropwise over 15minutes. Themixture was
then stirred at rt, and the reaction wasmonitored by TLC (2:3 EtOAc-
hexane). After 1 week, the mixture was concentrated under
diminished pressure, and the crude product was puriﬁed by column
chromatography (1:2 EtOAc-hexane) to give 0.14 g (70%) white solid.
Mp: 105–107 °C; [α]D = +6 (c 0.56, CHCl3); 1H NMR (CDCl3) δ (ppm):
10.89 (1H, br s, NH), 8.06–7.16 (22H, m, Ar), 7.02 (2H, d, J = 7.4 Hz,
Ar), 6.01 (1H, pseudo t, J = 9.2, 9.2 Hz, H-2′ or H-3′ or H-4′), 5.84–
5.78 (2H, m, H-2′ and/or H-3′ and/or H-4′), 4.86 (1H, d, J = 9.2 Hz,
H-1′), 4.63 (1H, dd, J = 12.3, < 1Hz, H-6′a), 4.50 (1H, dd, J = 12.3, 4.9 Hz,
H-6′b), 4.32 (1H, ddd, J = 9.2, 4.9, < 1 Hz, H-5′), 2.26 (3H, s, CH3); 13C
NMR (CDCl3) δ (ppm): 166.2, 165.6, 165.1, 164.8 (C = O), 151.9
(triazolone C = O), 145.6, 145.0 (triazolone C-3, Ts-C-1 or Ts-C-4),
133.7 (Ts-C-1 or Ts-C-4), 133.4–133.1, 130.0–127.9 (Ar), 76.6, 73.5,
72.6, 69.8, 69.0 (C-1′ – C-5′), 63.0 (C-6′), 21.5 (CH3). MS-ESI (m/z):
Calcd. for C43H36N3O12S+ [M + H]+: 818.2. Found: 818.5.
3.10. 3-(β-D-Glucopyranosyl)-1-tosyl-1H-1,2,4-triazol-5(4H)-one
(22)
Prepared from compound 21 (0.20 g, 0.24 mmol) according to
the general procedure (Section 3.2). Reaction time: 7 h. Puriﬁed by
column chromatography (9:1 CHCl3-MeOH) to yield 55 mg (56%)
colourless syrup. Rf = 0.54 (7:3 CHCl3-MeOH), [α]D = −7 (c 0.31,MeOH);
1H NMR (DMSO-d6) δ (ppm): 12.34 (1H, br s, NH), 7.84, 7.48 (2 × 2H,
2 d, J = 7.9 Hz in each, Ar), 5.24, 5.14, 5.02, 4.46 (4 × 1H, OH), 3.89
(1H, d, J = 9.2 Hz, H-1′), 3.64 (1H, dd, J = 11.9, 2.6 Hz, H-6′a), 3.22–
3.07 (5H, m, H-2′, H-3′, H-4′, H-5′, H-6′b), 2.41 (3H, s, CH3); 13C NMR
(CD3OD) δ (ppm): 154.4, 150.6, 147.7 (triazolone C = O, triazolone
C-3, Ts-C-1 or Ts-C-4), 135.7, 131.2 (2), 129.1 (2) (Ar), 82.2, 78.9, 76.0,
73.0, 70.9 (C-1′ – C-5′), 62.4 (C-6′), 21.7 (CH3). MS-ESI (m/z): Calcd.
for C15H20N3O8S+ [M + H]+: 402.1. Found: 402.3. Anal: Calcd for
C15H19N3O8S (M 401.39): C, 44.88; H, 4.77; N, 10.47. Found: C, 45.16;
H, 4.85; N, 10.42.
3.11. N1-Phenyl-N4-(2′,3′,4′,6′-tetra-O-benzoyl-β-D-
glucopyranosylcarbonyl)semicarbazide (25)
To a solution of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)
formamide30 (23, 2.5 g, 4.0 mmol) in anhydrous 1,2-dichloroethane
(50 mL) oxalyl chloride (0.68 mL, 8.0 mmol) was added, and the
mixture was reﬂuxed for 1 d. The reaction mixture was then con-
centrated under diminished pressure, and traces of oxalyl chloride
was removed by repeated co-evaporations with toluene. The re-
maining syrup was dissolved in anhydrous THF (50mL), the solution
was cooled to 0 °C and phenylhydrazine (0.6 mL, 6.0 mmol) was
added. Subsequently the reaction mixture was allowed to warm to
rt and stirred for 1 d. The solvent was then removed under reduced
pressure, and the residue was crystallized from diethyl ether to give
2.1 g (69% for two steps) pale yellow solid. Mp: 219–221; [α]D = −17
(c 0.51, CHCl3); 1H NMR (CDCl3) δ (ppm): 9.53, 9.47 (2 × 1H, 2 s, NH),
8.03–6.86 (25H, m, Ar), 6.21 (1H, s, NH), 5.89 (1H, pseudo t, J = 9.0,
8.5 Hz, H-2′ or H-3′ or H-4′), 5.75–5.64 (2H, m, H-2′ and/or H-3′ and/
or H-4′), 4.64 (1H, dd, J = 11.5, < 1 Hz, H-6′a), 4.42 (1H, dd, J = 11.5,
3.4 Hz, H-6′b), 4.15 (1H, d, J = 9.3 Hz, H-1′), 4.09 (1H, m, H-5′); 13C
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NMR (CDCl3) δ (ppm): 168.0, 166.4, 165.7, 165.1 (2), 154.1 (C = O),
147.6, 133.6–133.2, 129.8–128.3, 121.0, 113.1 (Ar), 76.4, 76.2, 73.2,
69.4, 69.0 (C-1′ – C-5′), 63.0 (C-6′). MS-ESI (m/z): Calcd. for
C42H36N3O11+ [M + H]+: 758.2. Found: 758.5.
3.12. N1-(tert-Butoxycarbonyl)-N2-phenyl-N4-(2′,3′,4′,6′-tetra-O-
benzoyl-β-D-glucopyranosylcarbonyl)semicarbazide (26)
To a solution of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)
formamide30 (23, 0.5 g, 0.80mmol) in anhydrous 1,2-dichloroethane
(12 mL) oxalyl chloride (136 μL, 0.16 mmol) was added, and the
mixture was heated at reﬂux temperature for 1 d. The reaction
mixture was then concentrated under diminished pressure, and
traces of oxalyl chloride was removed by repeated co-evaporations
with toluene. The remaining syrup was dissolved in anhydrous THF
(10 mL), the solution was cooled to 0 °C and PhNHNHBoc (0.25 g,
1.2 mmol) was added. Subsequently, the reaction mixture was
allowed to warm to rt and stirred for 3 h. The solvent was then
evaporated under reduced pressure and the residue was puriﬁed
by column chromatography (1:2 EtOAc-hexane) to obtain the title
compound 26 (0.35 g) as the ﬁrst than amide 23 (0.12 g) as the
second fraction. Yield of the title compound for two steps: 66% (cor-
rected with the recovered starting material 23). Mp: 192–194 °C
(white solid); [α]D = −7 (c 0.21, CHCl3); 1H NMR (DMSO-d6) δ (ppm):
10.03, 9.86 (2 × 1H, 2 br s, NH), 7.98–7.17 (25H, m, Ar), 6.03, 5.80,
5.68 (3 × 1H, 3 pseudo t, J = 9.4, 9.4 Hz in each, H-2′, H-3′, H-4′), 4.91
(1H, d, J = 9.4 Hz, H-1′), 4.57–4.41 (3H, m, H-5′, H-6′a, H-6′b), 1.34
(9H, s, C(CH3)3; 13C NMR (DMSO-d6) δ (ppm): 165.3 (2), 165.1, 164.6,
164.4, 154.5, 150.3 (C = O), 141.0, 133.7–133.4, 129.2–128.4, 124.0
(Ar), 80.6 (C(CH3)3), 75.5, 74.6, 74.0, 69.4, 68.6 (C-1′ – C-5′), 62.8 (C-
6′), 27.7 (C(CH3)3). MS-ESI (m/z): Calcd. for C47H44N3O13+ [M + H]+:
858.3. Found: 858.1.
3.13. 1-Phenyl-3-(2′,3′,4′,6′-tetra-O-benzoyl-β-D-glucopyranosyl)-
1H-1,2,4-triazol-5(4H)-one (27)
A: The solution of compound 25 (1.0 g, 1.32 mmol) in anhy-
drousm-xylene (40 mL) was heated at boiling temperature, and
the reactionwasmonitored by TLC (1:1 EtOAc-hexane). After total
consumption of the starting material (1 d), the solvent was
removed, and the residue was puriﬁed by column chromatog-
raphy (1:2 EtOAc-hexane) to give 0.36 g (37%) colourless syrup.
B: To a solution of compound 26 (0.23 g, 0.27 mmol) in anhy-
drous CH2Cl2 (10mL) triﬂuoroacetic acid (124 μL, 1.61mmol) was
added and the mixture was stirred at rt. After disappearance of
the starting material (4 d) monitored by TLC (2:3 EtOAc-hexane),
the solvent was removed under diminished pressure, and the
residue was puriﬁed by column chromatography (1:2 EtOAc-
hexane) to yield 0.17 g (87%) colourless syrup. Rf: 0.54 (1:1 EtOAc-
hexane); [α]D = +16 (c 0.61, CHCl3); 1HNMR (CDCl3) δ (ppm): 11.58
(1H, br s, NH), 8.00–7.83 (4 × 2H, 4 d, J = 7.0 Hz in each, Ar), 7.67
(2H, d, J = 7.8 Hz, Ar), 7.52–7.10 (15H, m, Ar), 6.06, 5.91, 5.80
(3 × 1H, 3 pseudo t, J = 9.4, 9.4 Hz in each, H-2′, H-3′, H-4′), 4.90
(1H, d, J = 9.4 Hz, H-1′), 4.69 (1H, dd, J = 12.5, 3.1 Hz, H-6′a), 4.57
(1H, dd, J = 12.5, 5.5 Hz, H-6′b), 4.35 (1H, ddd, J = 9.4, 5.5, 3.1 Hz,
H-5′); 13C NMR (CDCl3) δ (ppm): 166.2, 165.8, 165.1, 165.0 (C =O),
153.4 (triazolone C = O), 142.6 (triazolone C-3), 137.3, 133.5–
133.1, 129.9–128.3, 125.5, 118.7 (Ar), 76.8, 73.5, 72.7, 70.2, 69.2
(C-1′ – C-5′), 63.1 (C-6′). ESI-MS positive mode (m/z): calcd for
C42H34N3O10+ [M + H]+: 740.2. Found: 740.4.
3.14. 3-(β-D-Glucopyranosyl)-1-phenyl-1H-1,2,4-triazol-5(4H)-one
(28)
Prepared from compound 27 (0.23 g, 0.31 mmol) according to
the general procedure (Section 3.2). Reaction time: 6 h. Puriﬁed by
column chromatography (85:15 CHCl3-MeOH) to yield 94mg (95%)
white solid. Mp: 238–240 °C [α]D = +30 (c 0.40, MeOH); 1H NMR
(DMSO-d6 + 1 drop D2O) δ (ppm): 7.83 (2H, d, J = 7.8 Hz, Ar), 7.43 (2H,
pseudo t, J = 7.8 Hz, Ar), 7.21 (1H, t, J = 7.8 Hz, Ar), 4.04 (1H, d,
J = 9.4 Hz, H-1′), 3.69 (1H, dd, J = 11.7, 5.5 Hz, H-6′a), 3.46 (1H, pseudo
t, J = 9.4, 9.4 Hz, H-2′ or H-3′ or H-4′), 3.44 (1H, dd, J = 11.7, 3.1 Hz,
H-6′b), 3.30–3.25 (2H, m, H-2′ or H-3′ or H-4′, H-5′), 3.16 (1H, pseudo
t, J = 9.4, 9.4 Hz, H-2′ or H-3′ or H-4′); 13C NMR (DMSO-d6) δ (ppm):
152.6 (triazolone C =O), 145.7 (triazolone C-3), 137.7, 129.0 (2), 124.7,
117.9, 117.7 (Ar), 81.4, 77.5, 74.5, 71.1, 69.8 (C-1′ – C-5′), 61.1 (C-
6′). MS-ESI (m/z): Calcd. for C14H18N3O6+ [M +H]+: 324.1. Found: 324.2.
Anal: Calcd for C14H17N3O6 (M 323.30): C, 52.01; H, 5.30; N, 13.00.
Found: C, 52.09; H, 5.46; N,12.85.
3.15. 1-(2-Naphthyl)-3-(2′,3′,4′,6′-tetra-O-benzoyl-β-D-
glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (29)
To a solution of compound 19 (0.10 g, 0.15 mmol) in anhydrous
CH2Cl2 (3 mL) 2-naphthylboronic acid (52mg, 0.30mmol), Cu(OAc)2
(27 mg, 0.15 mmol) and Et3N (42 μL, 0.30 mmol) were added, and
the reaction mixture was stirred at rt. When the TLC (1:1 EtOAc-
hexane) showed total consumption of 20 (1 d), the solvent was
evaporated. The residue was puriﬁed by column chromatography
(2:3 EtOAc-hexane) to give 24mg (20%) pale yellow amorphous solid.
Rf: 0.51 (1:1 EtOAc-hexane); [α]D = +11 (c 0.44, CHCl3); 1H NMR
(CDCl3) δ (ppm): 11.89 (1H, br s, NH), 8.12 (1H, s, Ar), 7.97–7.20 (26H,
m, Ar), 6.10, 5.98, 5.84 (3 × 1H, 3 pseudo t, J = 9.2, 9.2 Hz in each,
H-2′, H-3′, H-4′), 4.95 (1H, d, J = 9.2 Hz, H-1′), 4.72 (1H, dd, J = 11.9,
2.6 Hz, H-6′a), 4.61 (1H, dd, J = 11.9, 5.3 Hz, H-6′b), 4.37 (1H, ddd,
J = 9.2, 5.3, 2.6 Hz, H-5′); 13C NMR (CDCl3) δ (ppm): 166.2, 165.8, 165.1
(2) (C = O), 153.7 (triazolone C = O), 142.9 (triazolone C-3), 134.8–
125.4, 118.0, 116.2 (Ar), 76.7, 73.5, 72.6, 70.3, 69.3 (C-1′ – C-5′), 63.1
(C-6′). ESI-MS positive mode (m/z): calcd for C46H36N3O10+ [M + H]+:
790.2. Found: 790.4.
3.16. 3-(β-D-Glucopyranosyl)-1-(2-naphthyl)-1H-1,2,4-triazol-
5(4H)-one (30)
Prepared from compound 29 (0.12 g, 0.15mmol) according to the
general procedure (Section 3.2). Reaction time: 4 h. Puriﬁed by
column chromatography (85:15 CHCl3-MeOH) to yield 48mg (84%)
colourless syrup. Rf = 0.43 (7:2 CHCl3-MeOH), [α]D = +33 (c 0.13,
MeOH); 1H NMR (DMSO-d6 + 1 drop D2O) δ (ppm): 8.31 (1H, s, Ar),
8.04–7.88, 7.54–7.45 (6H, m, Ar), 4.10 (1H, d, J = 9.4 Hz, H-1′), 3.69
(1H, dd, J = 11.7, 2.3 Hz, H-6′a), 3.50 (1H, pseudo t, J = 9.4, 9.4 Hz, H-2′
or H-3′ or H-4′), 3.47 (1H, dd, J = 11.7, 5.5 Hz, H-6′b), 3.34–3.29 (2H,
m, H-2′ or H-3′ or H-4′, H-5′), 3.21 (1H, pseudo t, J = 9.4, 9.4 Hz, H-2′
or H-3′ or H-4′); 13C NMR (DMSO-d6) δ (ppm): 152.7 (triazolone
C =O), 145.9 (triazolone C-3), 135.3, 133.0, 130.3, 128.9, 127.8, 127.6,
127.5, 127.4, 117.6, 114.5 (Ar), 81.4, 77.4, 74.6, 71.1, 69.8 (C-1′ – C-5′),
61.0 (C-6′). MS-ESI (m/z): Calcd. for C18H20N3O6+ [M + H]+: 374.1.
Found: 374.3. Anal: Calcd for C18H19N3O6 (M 373.36): C, 57.90; H,
5.13; N, 11.25. Found: C, 57.83; H, 5.31; N, 11.39.
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